The SPIRIT IV trial compared everolimus-eluting stents (EES) with paclitaxel-eluting stents (PES) in patients with coronary artery disease. The study enrolled 3687 patients across 66 U.S. sites, with no routine follow-up angiography. The primary endpoint was 1-year target-lesion failure, defined as cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization. EES showed a significant reduction in target-lesion failure (4.2% vs. 6.8%) and ischemia-driven revascularization (2.5% vs. 4.6%). EES were also noninferior to PES in the composite endpoint of cardiac death or target-vessel myocardial infarction. EES also reduced stent thrombosis (0.17% vs. 0.85%) and myocardial infarction (1.9% vs. 3.1%). These benefits were consistent across most subgroups, except for patients with diabetes, where no significant difference was observed. The study highlights the clinical superiority of EES in reducing adverse outcomes, with the exception of diabetes patients. The results emphasize the importance of large, randomized trials to evaluate differences between drug-eluting stents. The findings suggest that EES can achieve improved clinical outcomes without compromising safety. However, further research is needed to address differences in restenosis mechanisms and antiproliferative agent responses in diabetic patients.The SPIRIT IV trial compared everolimus-eluting stents (EES) with paclitaxel-eluting stents (PES) in patients with coronary artery disease. The study enrolled 3687 patients across 66 U.S. sites, with no routine follow-up angiography. The primary endpoint was 1-year target-lesion failure, defined as cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization. EES showed a significant reduction in target-lesion failure (4.2% vs. 6.8%) and ischemia-driven revascularization (2.5% vs. 4.6%). EES were also noninferior to PES in the composite endpoint of cardiac death or target-vessel myocardial infarction. EES also reduced stent thrombosis (0.17% vs. 0.85%) and myocardial infarction (1.9% vs. 3.1%). These benefits were consistent across most subgroups, except for patients with diabetes, where no significant difference was observed. The study highlights the clinical superiority of EES in reducing adverse outcomes, with the exception of diabetes patients. The results emphasize the importance of large, randomized trials to evaluate differences between drug-eluting stents. The findings suggest that EES can achieve improved clinical outcomes without compromising safety. However, further research is needed to address differences in restenosis mechanisms and antiproliferative agent responses in diabetic patients.